These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 8313355)

  • 1. Transforming growth factor-alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice.
    Phillips PC; Levow C; Catterall M; Colvin OM; Pastan I; Brem H
    Cancer Res; 1994 Feb; 54(4):1008-15. PubMed ID: 8313355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abrogation of head and neck squamous cell carcinoma growth by epidermal growth factor receptor ligand fused to pseudomonas exotoxin transforming growth factor alpha-PE38.
    Thomas SM; Zeng Q; Epperly MW; Gooding WE; Pastan I; Wang QC; Greenberger J; Grandis JR
    Clin Cancer Res; 2004 Oct; 10(20):7079-87. PubMed ID: 15501988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein.
    Arteaga CL; Hurd SD; Dugger TC; Winnier AR; Robertson JB
    Cancer Res; 1994 Sep; 54(17):4703-9. PubMed ID: 8062268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of a transforming growth factor alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE40).
    Pai LH; Gallo MG; FitzGerald DJ; Pastan I
    Cancer Res; 1991 Jun; 51(11):2808-12. PubMed ID: 2032221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells.
    Liu TF; Willingham MC; Tatter SB; Cohen KA; Lowe AC; Thorburn A; Frankel AE
    Bioconjug Chem; 2003; 14(6):1107-14. PubMed ID: 14624623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
    Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
    Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME
    Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small chimeric toxins containing only transforming growth factor alpha and domain III of Pseudomonas exotoxin with good antitumor activity in mice.
    Kihara A; Pastan I
    Cancer Res; 1994 Oct; 54(19):5154-9. PubMed ID: 7923133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
    Vassal G; Boland I; Terrier-Lacombe MJ; Watson AJ; Margison GP; Vénuat AM; Morizet J; Parker F; Lacroix C; Lellouch-Tubiana A; Pierre-Kahn A; Poullain MG; Gouyette A
    Clin Cancer Res; 1998 Feb; 4(2):463-8. PubMed ID: 9516937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
    Kioi M; Kawakami K; Puri RK
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma.
    Yuan X; Tabassi K; Williams JA
    Radiat Oncol Investig; 1999; 7(4):218-30. PubMed ID: 10492162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma.
    Hagan M; Yacoub A; Dent P
    Clin Cancer Res; 2004 Sep; 10(17):5724-31. PubMed ID: 15355899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
    Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
    J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
    Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
    Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGF-alpha-driven tumor growth is inhibited by an EGF receptor tyrosine kinase inhibitor.
    El-Obeid A; Hesselager G; Westermark B; Nistér M
    Biochem Biophys Res Commun; 2002 Jan; 290(1):349-58. PubMed ID: 11779176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo.
    Ekstrand AJ; James CD; Cavenee WK; Seliger B; Pettersson RF; Collins VP
    Cancer Res; 1991 Apr; 51(8):2164-72. PubMed ID: 2009534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
    Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
    Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model.
    Slagel DE; Feola J; Houchens DP; Ovejera AA
    Cancer Res; 1982 Mar; 42(3):812-6. PubMed ID: 7059979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors.
    De Jong KP; Stellema R; Karrenbeld A; Koudstaal J; Gouw AS; Sluiter WJ; Peeters PM; Slooff MJ; De Vries EG
    Hepatology; 1998 Oct; 28(4):971-9. PubMed ID: 9755233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.
    Rand RW; Kreitman RJ; Patronas N; Varricchio F; Pastan I; Puri RK
    Clin Cancer Res; 2000 Jun; 6(6):2157-65. PubMed ID: 10873064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.